lbtn وخبر

الموضوع في 'السوق الأمريكي للأوراق الماليه' بواسطة bukhaly, بتاريخ ‏20 مارس 2007.

  1. bukhaly

    bukhaly عضو جديد

    التسجيل:
    ‏21 يناير 2003
    المشاركات:
    763
    عدد الإعجابات:
    0
    خبر فرش
    Lifeline Biotechnologies Pursues Prospective Major Breakthrough in Breast Cancer Detection
    via COMTEX

    March 20, 2007

    RENO, Nev., Mar 20, 2007 (BUSINESS WIRE) --

    Lifeline Biotechnologies, Inc. (OTCPK: LBTN) today announced that it is nearing a major breakthrough in the early detection of breast cancer. The new experimental classifying algorithms, the basis for Lifeline's First Warning System(TM), demonstrate sensitivity of 100% (the ability to find lesions in the breast) and two additional algorithms documented a specificity (the ability to distinguish benign from cancerous lesions) of 84% and 91% with its new neural network system which is nearing ready for clinical testing on large patient data sets.

    Louis Keith, MD, PhD, Lifeline's Medical Director, stated, "For several decades medical researchers have struggled to find an accurate method for using the interpretation of thermal circadian data related to tumor growth in the breast as a detection modality. Many researchers believe the thermal data code of the breast's minute incremental temperatures changes are direct reflections of the breast's physiological activity and tumor growth."

    Dr. Keith went on to say, "One in five women with breast cancer die of the disease; early detection is extremely important and should be the point of reference in evaluating any screening program. Past studies have shown that the characteristics of rhythmic changes in skin temperature of clinically healthy cancerous breasts are real and measurable. The superficial thermal patterns measured on the surface of the breast are related to tissue metabolism and vascularization within the underlying tissue. Cancer development appears to generate its own thermal signatures, and the complexity or lack thereof may be a reflection of its degree of development."

    According to Lifeline's CEO, Jim Holmes, "These physiological phenomena led to the initial research in the mid-1980s by Lifeline's founder Dr. William Reeves and resulted in the development of prototype computer microprocessors capable of capturing these thermal aberrations as well as the development of the 'First Warning System(TM)' and ultimate patent protection of the technology and software."

    About Lifeline Biotechnologies

    SAFE HARBOR: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

    SOURCE: Lifeline Biotechnologies, Inc.

    Lifeline Biotechnologies, Inc. Investor Relations Rodney Marvel, 866-THE-APPLE www.lbtn.com
     
  2. bukhaly

    bukhaly عضو جديد

    التسجيل:
    ‏21 يناير 2003
    المشاركات:
    763
    عدد الإعجابات:
    0
    تداول قوي
     
  3. goodluck

    goodluck عضو جديد

    التسجيل:
    ‏5 يوليو 2005
    المشاركات:
    176
    عدد الإعجابات:
    0
    اي والله تداول قوي:eek:
     
  4. الكتروني

    الكتروني موقوف

    التسجيل:
    ‏11 يوليو 2005
    المشاركات:
    181
    عدد الإعجابات:
    0
    للمتابعه الجاده
     
  5. bukhaly

    bukhaly عضو جديد

    التسجيل:
    ‏21 يناير 2003
    المشاركات:
    763
    عدد الإعجابات:
    0
    خبر
    Lifeline Biotechnologies, Inc. Prepares for Patent Application Filing
    Monday April 30, 11:02 am ET


    RENO, Nev.--(BUSINESS WIRE)--Lifeline Biotechnologies, Inc. (Pink Sheets:LBTN - News) today announced the Company is preparing to file a patent application covering certain advancements it has achieved as a result of its continued research and development program concerning it First Warning System(TM) a process to assist in the early detection of breast cancer.
    ADVERTISEMENT


    Jim Holmes, CEO of Lifeline, said, "We have received the preliminary draft of a patent application from the Company's corporate patent counsel. The application covers certain Neural Net Based Classification of Breast Cancer with blind thermal data screening for detecting breast cancer in women. This patent will add substantially to the intellectual property of the Company in terms of protecting its ability to use the temperatures given off by the earliest and smallest breast tumors as a means of detecting breast cancer at a stage when treatment is less invasive and less costly."

    Dr. Louis Keith, Lifeline's Medical Director stated, "The new technology represents a refinement designed to minimize the likelihood of false positive results with the First Warning System(TM)."

    Share Exchange, Series B Convertible Preferred for Common Shares

    The cut-off date for the previously announced exchange of series B preferred stock for common stock, for shareholders to submit their common shares to Lifeline's Transfer Agent, OTC Corporate Stock Transfer, Jericho, NY, has been extended to May 18, 2007. The exchange is for one share of preferred, valued at $1.00 each for each 1600 shares of common stock submitted. The value of the common stock is $.000625 per share, a premium over the current market price. To qualify for the exchange, shareholders must submit a minimum of 100,000 common shares. The Series B Preferred Stock is valued at $1.00 per share for future conversion purposes. The Company will be sending an Information Statement disclosing the terms and conditions of the exchange. In addition, particulars concerning the exchange will be posted on Lifeline's website www.lbtn.com.

    About Lifeline Biotechnologies, Inc.

    Lifeline Biotechnologies, Inc. has recently reacquired the First Warning System(TM) which it had sold in 2006. The Company will focus on completing the development of the First Warning System(TM), designed to assist in the early detection of breast cancer. The underlying technology, upon which the First Warning System(TM) is based, holds the possibility of eliminating over 90% of unnecessary breast biopsies performed each year. The potential savings could reach $2.8 billion annually. Additionally, the First Warning System(TM) could conceivably eliminate the need for suggested MRIs, a savings of another $1.3 billion. Upon successful completion of the development of the First Warning System(TM), conducting clinical trials and obtaining FDA pre-marketing clearance, Lifeline will commence marketing its breast cancer early detection system. Of the approximately $138 billion spent on cancer each year, Lifeline could potentially save the healthcare industry up to $4.1 billion annually. More information is available at the Company's website: www.lbtn.com.

    Safe Harbor: This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements. Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.

    To automatically receive instant updates, press releases, and other information on this and other Big Apple Consulting USA companies, please visit www.bigappleconsulting.com/compro.php and download your FREE copy of Big Apple ComPro.